Publications by authors named "Edgar Wood"

Claim this Profile
D
Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.
Andrew L McIver, Weihe Zhang, Qingyang Liu, Xinpeng Jiang, Michael A Stashko, Edgar Wood

ChemMedChem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.
Xiaodong Wang, Jing Liu, Weihe Zhang, Michael A Stashko, James Nichols, Edgar Wood

ACS Med Chem Lett· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors.
Edgar R Wood, Randy Bledsoe, Jing Chai, Philias Daka, Hongfeng Deng

J Biol Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
Hong Lin, Dennis S Yamashita, Jin Zeng, Ren Xie, Wenyong Wang, Edgar R Wood

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
Edgar R Wood, Lisa Shewchuk, Anne Hassel, Jim Nichols, Anne T Truesdale

Biochem Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
Alex G Waterson, Kimberly G Petrov, Keith R Hornberger, Robert D Hubbard, Douglas M Sammond, Edgar R Wood

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Tara R Rheault, Thomas R Caferro, Scott H Dickerson, Kelly H Donaldson, Michael D Gaul, Edgar R Wood

Bioorg Med Chem Lett· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Kirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, Thomas R Caferro, Stanley D Chamberlain, Edgar R Wood

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
Robert D Hubbard, Scott H Dickerson, Holly K Emerson, Robert J Griffin, Michael J Reno, Edgar R Wood

Bioorg Med Chem Lett· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
Dirk A Heerding, Nelson Rhodes, Jack D Leber, Tammy J Clark, Richard M Keenan, Edgar R Wood

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Nelson Rhodes, Dirk A Heerding, Derek R Duckett, Derek J Eberwein, Victoria B Knick, Edgar R Wood

Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases.
Edgar R Wood, Lisa M Shewchuk, Byron Ellis, Perry Brignola, Ronald L Brashear

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Tona M Gilmer, Louann Cable, Krystal Alligood, David Rusnak, Glenn Spehar, Edgar R Wood

Cancer Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aza-stilbenes as potent and selective c-RAF inhibitors.
Octerloney McDonald, Karen Lackey, Ronda Davis-Ward, Edgar Wood, Vicente Samano

Bioorg Med Chem Lett· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Kimberly G Petrov, Yue-Mei Zhang, Malcolm Carter, G Stuart Cockerill, Scott Dickerson, Edgar R Wood

Bioorg Med Chem Lett· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Alex G Waterson, Kirk L Stevens, Michael J Reno, Yue-Mei Zhang, Eric E Boros, Edgar R Wood

Bioorg Med Chem Lett· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
Michael J Alberti, Elizabeth P Auten, Karen E Lackey, Octerloney B McDonald, Edgar R Wood

Bioorg Med Chem Lett· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Edgar R Wood, Anne T Truesdale, Octerloney B McDonald, Derek Yuan, Anne Hassell

Cancer Res· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.
Edgar R Wood, Lee Kuyper, Kimberly G Petrov, Robert N Hunter, Philip A Harris

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.
Yue-Mei Zhang, Stuart Cockerill, Stephen B Guntrip, David Rusnak, Kathryn Smith, Edgar Wood

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
Micheal D Gaul, Yu Guo, Karen Affleck, G Stuart Cockerill, Tona M Gilmer, Edgar R Wood

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
Perry S Brignola, Karen Lackey, Sue H Kadwell, Christine Hoffman, Earnest Horne, Edgar R Wood

J Biol Chem· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis